Major Study Confirms Maternal RSV Vaccination Reduces Infant Hospitalizations by 80%

Impact of Maternal RSV Vaccination on Infant Hospitalizations

A groundbreaking study presented at the ESCMID Global 2026 conference has unveiled compelling evidence regarding the benefits of maternal vaccination against respiratory syncytial virus (RSV). This extensive research underscores a dramatic reduction in hospitalizations for young infants, with findings showing an 80% decline in cases when mothers received the vaccine at least two weeks prior to birth.

Understanding RSV and Its Risks

RSV is notorious for causing severe respiratory illnesses in infants and young children. It can lead to conditions such as bronchiolitis and pneumonia, making it a leading cause of infant hospitalizations globally. Early infections are particularly concerning, as they are associated with lasting health issues like recurrent wheezing, asthma, and persistent lung problems.

In England, a national maternal vaccination initiative was launched on September 1, 2024, offering the Bivalent Prefusion F vaccine to expectant mothers starting from their 28th week of gestation. The program aims to reduce the severe impacts of RSV on infants, particularly in the context of rising hospitalization rates.

Methodology of the Study

The research, conducted by the UK Health Security Agency (UKHSA), analyzed national datasets linking NHS maternity records, immunization data, and hospital admissions. It included data from 289,399 infants born between September 2, 2024, and March 24, 2025, encompassing nearly 90% of births in that timeframe.

Among the examined infants, there were 4,594 recorded hospitalizations linked to RSV. Notably, while infants from unvaccinated mothers constituted 55% of the study group, they accounted for an alarming 87.2% of the total hospitalizations. In contrast, those infants whose mothers were vaccinated showed significantly reduced hospitalization rates, with vaccine efficacy estimated at 81.3% compared to their unvaccinated counterparts.

Key Findings and Implications

UKHSA epidemiologist Matt Wilson, the lead author of the study, remarked on the significance of the findings, stating, "This is the largest investigation to date assessing the impact of maternal RSV vaccination on infant hospitalizations. Our results provide robust evidence that vaccination substantially safeguards young infants against severe illnesses associated with RSV."

The study also explored the effectiveness of the vaccine for preterm infants, revealing an efficacy of 69.4% when vaccination occurred at least two weeks before delivery. These results are especially relevant for preterm infants, who are particularly susceptible to severe RSV infections.

Wilson emphasized the importance of timing in maternal vaccination, noting that the protective effects increased the longer the period between vaccination and birth. Effectiveness approached 85% when mothers were vaccinated at least four weeks before delivery, highlighting a clear trend between increased protection and vaccination timing.

Conclusion

The implications of this study cannot be understated. With substantial evidence supporting the effectiveness of maternal vaccination against RSV, there is an urgent need to ensure that expectant mothers are informed about the benefits of getting vaccinated. This study not only advocates for public health initiatives focusing on maternal health but also stresses the importance of safeguarding the most vulnerable segment of our population – young infants.

By fostering awareness and encouraging participation in maternal vaccination programs, we can significantly lower the risk of RSV hospitalizations and improve overall infant health outcomes, carving a path for a healthier future generation.